No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
HK Stock MarketDetailed Quotes
02196 FOSUN PHARMA
- 11.640
- +0.120+1.04%
Trading Apr 18 10:53 CST
31.11BMarket Cap11.76P/E (TTM)
11.660High11.440Low884.07KVolume11.520Open11.520Pre Close10.25MTurnover0.16%Turnover Ratio11.76P/E (Static)2.67BShares23.34052wk High0.62P/B6.42BFloat Cap11.32052wk Low0.46Dividend TTM551.94MShs Float80.880Historical High0.460Dividend LFY1.91%Amplitude6.197Historical Low11.595Avg Price500Lot Size3.95%Div YieldTTM3.95%Div Yield LFY
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Fosun Pharmaceutical (02196.HK): Fuhong Hanlin was approved for drug clinical trials
Gelonghui, April 17 | Fosun Pharmaceutical (02196.HK) announced that the company's holding subsidiary Shanghai Fuhong Hanlin Biotechnology Co., Ltd. and its holding subsidiary (hereinafter collectively referred to as “Fuhong Hanlin”) recently received approval from the State Drug Administration to conduct clinical trials with HLX53 (i.e. anti-Tigit FC fusion protein) in combination with Hans form (i.e. slulizumab injection) and Hanbetai (i.e. bevacizumab injection) for first-line treatment of locally advanced or metastatic hepatocellular carcinoma (HCC). Fu Hong Hanlin plans to be in China after the conditions are met (excluding Hong Kong, Macao and Taiwan regions, below
Fosun Pharmaceutical (02196.HK) held a board meeting on April 29 to consider and approve the first quarter results
Gelonghui, April 17, 丨 Fosun Pharmaceutical (02196.HK) announced that it will hold a board meeting on April 29, 2024 (Monday) to consider, approve and publish the first quarter results of the company and its subsidiaries for the three months ended March 31, 2024.
復星醫藥：董事會會議日期
Fosun Pharmaceutical (600196.SH): Sodium phosphonate injection accepted for drug registration application
Gelonghui, April 17 | Fosun Pharmaceutical (600196.SH) announced that the drug registration application for sodium phosphonate injection from the holding subsidiary Guilin Southern Pharmaceutical Co., Ltd. was recently accepted by the State Drug Administration. This new pharmaceutical chemical is intended for use in (1) cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS); and (2) acyclovir-resistant herpes simplex virus (HSV) cutaneous mucosal infections in immunodeficiency patients.
Hong Kong Stock Concept Tracking | Novo Nordisk's new weight loss drug clinical approval industry in China will usher in a period of breakthrough results (with concept stocks)
On April 10, the official website of the Drug Evaluation Center of the State Drug Administration announced that the clinical trial application for Novo Nordisk's Class 1 new drug amycretin tablets was accepted.
Fosun Pharmaceutical (02196): Fuhong Hanlin plans to guarantee Hanlin Pharmaceuticals's financing debt with a principal amount not exceeding 150 million yuan from China Construction Bank
Fosun Pharmaceutical (02196) issued an announcement. On April 9, 2024, the company's holding subsidiary Shanghai Fuhong Hanlin Biotech...
Comments
HSI Slides 342 Pts; Techs & Pharmas Gloom
$Hang Seng Index(800000.HK$ concluded the day at 19,617, down 342 pts or 1.7%. $Hang Seng China Enterprises Index(800100.HK$ sagged 131 pts or 2% to 6,601. $Hang Seng TECH Index(800700.HK$ faded 137 pts or 3.5% to 3,824. The turnover aggregated $106.657 billion.
Techs slid as the market continued to be watchful of the Sino-US relations:
$BABA-SW(09988.HK$ dived 3.2% to $84.1.
$TENCENT(00700.HK$ sank 1.9% to $338.4.
$MEITUAN-W(03690.HK$ , $XIAOMI-W(01810.HK$ , ...
Techs slid as the market continued to be watchful of the Sino-US relations:
$BABA-SW(09988.HK$ dived 3.2% to $84.1.
$TENCENT(00700.HK$ sank 1.9% to $338.4.
$MEITUAN-W(03690.HK$ , $XIAOMI-W(01810.HK$ , ...
1
ColumnsExpert Meeting Minutes | Seven Development Trends of the China Medical Aesthetics Industry
Core point
1. In the past three years, China's medical beauty industry has undergone earth-shaking changes, and non-surgical products occupy the mainstream
2. The brand is a marketing tool and a social contract for the legal entity to face society. Last year, it began to issue documents on supervising medical aesthetics, focusing on doctors' qualifications, marketing, and the capabilities of three types of ...
1. In the past three years, China's medical beauty industry has undergone earth-shaking changes, and non-surgical products occupy the mainstream
2. The brand is a marketing tool and a social contract for the legal entity to face society. Last year, it began to issue documents on supervising medical aesthetics, focusing on doctors' qualifications, marketing, and the capabilities of three types of ...
The domestic COVID-19 oral drug Azifodine is planned to be sold online, and $FOSUN PHARMA(02196.HK$ shares were opened 12% higher to 29 yuan.
$Pfizer(PFE.US$$AIM VACCINE(06660.HK$
$Pfizer(PFE.US$$AIM VACCINE(06660.HK$
In terms of allocation of Chinese stocks, it is suggested to focus on three main lines:
First, under the optimization of epidemic prevention, the repair market of damaged plates in the early stage, such as biomedical, aviation, wine travel and other plates; Second, under the demand of stable growth, the industry policy margin is loose, such as the real estate industry chain and the Internet and other industries; Third, under the theme of security for a long time, energy security, self contro... 7
2
Bloomberg: Chinese mRNA Shot Beat Sinovac as Booster But Caused More Fevers
https://alphaedgeinvesting.com/2022/06/02/bllomberg-chinese-mrna-shot-beat-sinovac-as-booster-but-caused-more-fevers/
$Sinovac Biotech(SVA.US$ $FOSUN PHARMA(02196.HK$ $Shanghai Fosun Pharmaceutical(600196.SH$ $CanSino Biologics Inc.(688185.SH$ $CANSINOBIO(06185.HK$ $Walvax Biotechnology(300142.SZ$ $Chongqing Zhifei Biological Products(300122.SZ$
$Sinovac Biotech(SVA.US$ $FOSUN PHARMA(02196.HK$ $Shanghai Fosun Pharmaceutical(600196.SH$ $CanSino Biologics Inc.(688185.SH$ $CANSINOBIO(06185.HK$ $Walvax Biotechnology(300142.SZ$ $Chongqing Zhifei Biological Products(300122.SZ$
Read more
Analysis
Price Target
No Data
Heat List
HK
Overall
Symbol
Latest Price
%Chg